Company profile
DNA synthesis technology to ignite the engineering biology revolution
Spearheading a radical new approach to gene synthesis to improve access to high-quality, gene-length DNA. Redefine possible.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jul 2017 to 30 Jun 2018
Due to concerns regarding antibiotic resistance and consumer preference for meat which is antibiotic-free, use antibiotic growth promoters (which previously suppressed certain bacterial diseases) in livestock are no longer permitted. This has resulted in an increase in rates of diseases such as necrotic enteritis (NE) in poultry and enteritis in swine cau...
1 Apr 2017 to 31 Mar 2019
In light of rapidly emerging bacterial resistance to antibiotics, novel antimicrobials that are more refractory to resistance development are urgently needed. C. difficile infections (CDI) driven by the emergence of highly virulent and antibiotic resistant strains have, over the last two decades, become more severe and more difficult to treat. They are no...
1 Aug 2014 to 31 Oct 2015
In light of rapidly emerging bacterial resistance to antibiotics, novel antimicrobials that are more refractory to resistance development are urgently needed. This project will test the feasibility of using targeted delivery of potent and highly specific novel antibiotic compounds. We will evaluate the feasibility of our approach in the context of Clostri...
1 Apr 2014 to 31 Dec 2015
Rabies is an acute, lethal disease caused by a virus infection of the central nervous system. The rabies virus is most often spread by a bite and saliva from an infected (rabid) animal e.g., dogs, bats & raccoons (disease vector). Virtually 100% of those infected with rabies who do not receive post exposure vaccination will die. This application is for a ...
1 Jun 2013 to 30 Nov 2014
This project aims to demonstrate the feasibility of utilising naturally occuring bacteria and phages as the basis of a novel Clostridium difficile (C.diff) therapy as an alternative to antibiotics.
1 Apr 2013 to 31 Mar 2014
This project will assess the feasibility of generating a vaccine technology platform using a novel virus- like particle (VLP) approach. Such a platform could be used to produce a range of highly effective yet safe vaccines that are rapid to respond to virus change, scalable and relatively cheap to manufacture compared to conventional killed virus vaccines...
1 Aug 2012 to 30 Nov 2012
The study will investigate the feasibility of applying novel methodologies in bioprocessing in order to generate a vaccine technology platform that can be deployed across a range of highly immunogenic, effective and relatively cheap to produce vaccines.
